[Establishing the model of kappaB-decoy inhibiting the activity of NF-kappaB in PC12 cells].
OBJECTIVE
Observing the time course and establishing the model of kappaB-decoy oligodeoxynucleotides (rcB-decoy) inhibiting the activity of NF-kappaB in the PC12 cells.


METHODS
PC12 cells cultivating in the 6 wells plate were divided into 3 groups, experimental group: adding kappaB-decoy complex (6 microg DNA/well), the control group: adding scrambled-decoy complex, the normal group: adding lipid-Lipofectamine 2000, transfer and cultivate 48 h, then lipopolysaccharide (LPS, 200 ng/ml) was added in the cells for 0.5-4 h. The immunocytochemistry and Western blot were used to measure the expression or the activity of NF-kappaB in PC12 cells.


RESULTS
In PC12 cells, compared with normal group, the expression of NF-kappaB enhanced obviously with the time of the stimulation of LPS in scrambled-decoy treated control group (P < 0.01), in 2-4 h the level reached the peak; the expression of NF-kappaB showed the stable level with the time of the stimulation of LPS in kappaB-decoy treated experimental group, compared with the control group, the expression levels were obviously lower than the respective time point of control groups (P < 0.01).


CONCLUSIONS
kappaB-decoy could reduce the expression of NF-kappaB in the normal PC12 cells and inhibit the activity of NF-cB in the pathologic PC12 cells.
Wang
Dong-mei
DM
Department of Medical Function, Dalian Medical University, Dalian 116044, China.
Gong
De-zheng
DZ
Yin
Sheng-ming
SM
Yu
De-qin
DQ
Xu
Hong
H
Xu
Jing
J
Zhao
Jie
J
Sun
Yi-ping
YP
D000818:Animals; D002478:Cells, Cultured; D008070:Lipopolysaccharides / Q000494:pharmacology; D016328:NF-kappa B / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D009838:Oligodeoxyribonucleotides / Q000494:pharmacology*; D016716:PC12 Cells; D051381:Rats
D008070:Lipopolysaccharides; D016328:NF-kappa B; C468119:NF-kappaB decoy; D009838:Oligodeoxyribonucleotides